Location:Home > mesothelioma news > NanoString Highlights Research Presented at the 2018 Annual Meeting of the Society of Immunotherapy

NanoString Highlights Research Presented at the 2018 Annual Meeting of the Society of Immunotherapy

Time:2018-11-08 18:13mesothelioma | mesothelioma lawyers Website Click:

financial content financialcontent.com stock quote stock quotes stock charts

By: NanoString Technologies, Inc. via GlobeNewswire News Releases

November 07, 2018 at 16:09 PM EST

NanoString Highlights Research Presented at the 2018 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)

NanoString Highlights Research Presented at the 2018 Annual Meeting of the Society of Immunotherapy

Includes Data from More than Twenty-Five Studies, Including Six Using GeoMx Digital Spatial Profiler

SEATTLE, Nov. 07, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of numerous advances in understanding of immune response and cancer immunotherapy using the nCounter® and GeoMx™ platforms that will be presented at the 33nd Annual Meeting of the Society of Immunotherapy for Cancer (SITC).

“We are thrilled to see a number of high-profile abstracts that include data from our GeoMx Digital Spatial Profiler at the 2018 SITC conference,” said Brad Gray, president and chief executive officer of NanoString. “The ability to quantify high-plex protein and RNA simultaneously can be a powerful tool for identifying and validating biomarkers, especially for applications in immuno-oncology.”

More than 25 abstracts using NanoString’s nCounter platform will be presented at the SITC Annual Meeting, being held at the Walter E. Washington Convention Center in Washington, D.C., Nov. 7-11, 2018. The research being presented spans a wide breadth of applications, including biomarker development, the study of immune responsiveness and resistance, and digital pathology.

Six studies included the use of NanoString’s GeoMx Digital Spatial Profiler (DSP) platform in immuno-oncology research.  These abstracts include numbers 031, P113, P131, P389, P428 and P429 that are included in the table below. DSP allows for digital quantification of protein and gene expression from discrete regions of FFPE tissue in an automated and multiplex format.  DSP is expected to be commercially available with the launch of a new instrument planned for mid-2019, and is currently accessible through the company’s Technology Access Program (TAP). NanoString is currently accepting applications for the TAP for its DSP technology at TAP@Nanostring.com.  

Each year, SITC recognizes publications that demonstrated excellence in scientific research with its Journal for ImmunoTherapy of Cancer (JITC) best paper awards.  The 2018 JITC “Best Basic Science Paper” was awarded for “Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA),” to a team led by NanoString researchers that included, Patrick Danaher, Ph.D., Sarah Warren, Ph.D., Rongze Lu, Ph.D., Josue Samayoa, Ph.D., Amy Sullivan, B.S., Irena Pekker, Ph.D., Brett Wallden, M.S., Francesco M. Marincola, M.D., and Alessandra Cesano, M.D., Ph.D.

NanoString will host a Key Opinion Leader Dinner for Digital Spatial Profiling on the evening of Thursday, Nov. 8th. The dinner features presentations by leading academic and biopharma researchers on the use of nCounter gene expression and GeoMx Digital Spatial Profiling technologies to discover biomarkers for treating bladder cancer and melanoma.

At the 2018 SITC Annual Meeting, NanoString will showcase its nCounter platform, IO360 and Data Analysis and Digital Spatial Profiling at booth #600.

Abstract #   Title   Presenting Author  
O31


  Tumor infiltrating lymphocyte recruitment after peri-lymphatic IRX-2 cytokine immunotherapy in resectable breast cancer and head and neck carcinoma

  David Page, MD
Providence Portland Cancer Center, Portland, OR,
USA
 
O45

  Refractory renal cell cancer (RCC) exhibits high adenosine A2A receptor (A2AR) expression and prolonged survival following treatment with the A2AR antagonist, CPI-444   Lawrence Fong, MD
University of California, San Francisco, CA, USA
 
P25

  Consistent pharmacodynamics and immunological responses to the TLR9 agonist, SD-101, following intratumoral injection in multiple cancer types   Albert Candia, PhD
Dynavax Technologies, Berkeley, CA, USA
 
P35

  Development of biomarkers to assess adenosine generation & activity in support of clinical trials conducted with the adenosine receptor antagonist AB928   Daniel DiRenzo, PhD
Arcus Biosciences, Hayward, CA, USA
 
P43


  The presence of exhausted CD8+ T cells identifies a subset of immunogenic ER+ breast cancer patient tumors


  Colt Egelston, PhD
Beckman Research Institute, City of Hope, Duarte,
CA, USA
 
P53

  X4P-001, an orally bioavailable CXCR4 antagonist, increases immune cell infiltration and tumor inflammatory status in the microenvironment of melanoma   Robert Andtbacka, MD
Huntsman Cancer Institute, Salt Lake City, UT, USA
 
P54

  Adenosine signature genes associate with tumor regression in renal cell carcinoma (RCC) patients treated with the adenosine A2A receptor (A2AR) antagonist, CPI-444   Andrew Hotson, PhD
Corvus Pharmaceuticals, Burlingame, CA, USA
 
P67

  Innovative combinatorial approach to characterize the immune landscape and analyze the tumor response after anti-PD-1 blockade in a 3D ex-vivo tumoroid system of non-small cell lung cancer   Melba Marie Page, PhD
Nilogen Oncosystems, Tampa, FL, USA
 
P87


  Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a Probody therapeutic antibody prodrug targeting PD-L1, in a phase 1/2a trial

  Luc R. Desnoyers, PhD
CytomX Therapeutics, Inc., South San Francisco, CA,
USA
 
P113

  Digital spatial profiling of bone-marrow infiltrating immune cells in acute myeloid leukemia

  Sergio Rutella, MD, PhD
Nottingham Trent University, Nottingham, UK
 
P131


  High-plex predictive marker discovery for melanoma immunotherapy treated patients using NanoString® Digital Spatial Profiling

  David Rimm, MD, PhD
Yale University School of Medicine, New Haven, CT,
USA
 
P136

  Genetic immunosignatures associate with progression-free survival in advanced soft tissue sarcoma patients treated on a Phase 2 trial of the VEGF receptor inhibitor axitinib plus pembrolizumab   Breelyn Wilky, MD
University of Miami - SCCC, Miami, FL, USA
 
P139

  "Pharmacodynamic effects of CA170, a first-in-class small molecule oral immune checkpoint inhibitor (ICI) dually targeting V-domain Ig suppressor of T-cell   Funda Meric-Bernstam, MD
MD Anderson Cancer Center, Houston, USA
 
P327

  Higher dose single-agent intratumoral G100 (a TLR4 agonist) results in increased biomarker activity and improved clinical outcomes in patients with follicular lymphoma   Ahmad Halwani, MD
Huntsman Cancer Institute, Salt Lake City, UT, USA
 
P349

  Spatial distribution analysis reveals increased PD1 expression on cytotoxic T cells leading to tumor regression upon combined MEK and HDAC inhibition in spontaneous PDAC mouse model   Phyllis Cheung, PhD
University Hospital Essen, DKFZ, Essen, Germany
 
P354

  Co-clinical trials of MEK inhibitor, anti PD-L1 and anti CTLA-4 combination treatment in Non-Small Cell Lung Cancer

  Pierre-Olivier Gaudreau
MD Anderson Cancer Center, Houston, USA
 
P360

  Enhanced anti-tumor efficacy of mesothelin-targeted immunotoxin LMB-100 combined with anti-PD-1 antibody

  Qun Jiang, PhD
National Institutes of Health, Bethesda, MD, USA
 
P389

  Digital spatial profiling on uveal melanoma tissue treated with combined radiofrequency ablation and ipilimumab

  Trieu My Van, PhD
NKI/Nanostring, Amsterdam, Netherlands
 
P428

  Spatially-resolved, high-plex digital profiling enables characterization of complex immune biology of the colorectal cancer microenvironment   Sarah Church, PhD
NanoString Technologies, Seattle, WA, USA
 
P429


  Integrative spatially-resolved, high-plex digital profiling enables characterization of complex immune biology in the tumor microenvironment of mesothelioma

  Carmen Ballesteros Merino, PhD, Providence Portland Cancer Center, Portland, OR,
USA
 
P450

  The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, displays immunomodulatory activity and enhances immune checkpoint blockade in syngeneic mouse models   Luis Carvajal, PhD
Aileron Therapeutics, Inc., Cambridge, MA, USA
 
P460

  Chemotherapy induced immunogenic cell death and response to STING agonist in high-grade serous ovarian cancer

  Sarah Nersesian, MSc
Queen's University, Kingston, ON, Canada
 
P468

  Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod   Mariya Rozenblit, MD
Yale University, Connecticut, CT, USA
 
P564

  Interleukin-6 gene expression is highly upregulated in immune checkpoint mediated enterocolitis

  Daniel Johnson, MD
MD Anderson Cancer Center, Houston, TX, USA
 
P597

  Reovirus infection of prostate cancer induces upregulation of the negative regulators PD-L1 and BTLA

  Nicola Annels, PhD
The University of Surrey, Guildford, UK
 
P614

  Nano-Pulse Stimulation™ of murine melanoma and mammary carcinoma is a physical modality that eliminates the treated tumor by regulated cell death and induces innate and adaptive immune responses   Amanda McDaniel, BA
Pulse Biosciences, Burlingame, CA, USA
 
P650

  Selective CD47 immune checkpoint targeting on tumor cells modulates the tumor microenvironment to enhance macrophage tumoricidal function   Vanessa Buatois, PhD
Novimmune SA, Geneva, Switzerland
 

About NanoString Technologies, Inc.

Copyright infringement? Click Here!